Targeting a specific type of lung cancer using the body's immune system
Targeting LKB1-null lung adenocarcinoma with innate immune system
['FUNDING_R01'] · EMORY UNIVERSITY · NIH-10886819
This study is looking at a tough type of lung cancer that has a specific gene mutation and is trying to find out how the body's immune system can be used to fight it, especially by comparing how male and female bodies respond, which could help develop better treatments for patients with this condition.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | EMORY UNIVERSITY (nih funded) |
| Locations | 1 site (ATLANTA, UNITED STATES) |
| Trial ID | NIH-10886819 on ClinicalTrials.gov |
What this research studies
This research investigates lung adenocarcinoma that has mutations in the LKB1 gene, which is often resistant to standard cancer therapies. The study aims to understand how the innate immune system can be harnessed to target these cancer cells, particularly focusing on the differences in immune responses between male and female hosts. Using a genetically engineered mouse model, researchers will explore the mechanisms behind the immune system's ability to eliminate LKB1-mutant lung cancer. This could lead to new therapeutic strategies for patients with this challenging form of lung cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with lung adenocarcinoma that has LKB1 mutations, particularly those who have not responded to existing therapies.
Not a fit: Patients with lung adenocarcinoma that does not have LKB1 mutations may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to innovative treatments that effectively target LKB1-mutant lung adenocarcinoma, improving outcomes for patients with this type of cancer.
How similar studies have performed: While the approach of targeting innate immunity in cancer is being explored, this specific focus on LKB1-null lung adenocarcinoma is relatively novel and has not been extensively tested.
Where this research is happening
ATLANTA, UNITED STATES
- EMORY UNIVERSITY — ATLANTA, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: ZHOU, WEI — EMORY UNIVERSITY
- Study coordinator: ZHOU, WEI
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Cancer Model, Cancer cell line, CancerModel